Valneva SE (VALN) Other Non Operating Income (2021 - 2026)
Valneva SE (VALN) posted Other Non Operating Income of -$3.5 million for Q1 2026, down 233.91% sequentially from -$1.0 million in Q4 2025, and down 190.62% YoY from $3.9 million in Q1 2025.
Analysis
Valneva SE (VALN) Other Non Operating Income (2021 - 2026) Analysis & Trends
Valneva SE has reported Other Non Operating Income for 6 years, with the latest figure at -$3.5 million in Q1 2026.
- Quarterly Other Non Operating Income fell 190.62% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.4 million (down 264.67% YoY) and the FY2025 annual result came in at -$8.4 million, down 341.99% from the prior year.
- Other Non Operating Income eased to -$3.5 million in Q1 2026 per VALN's latest filing, from -$1.0 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $14.2 million in Q4 2022 and troughed at -$16.5 million in Q3 2025.
- A 5-year average of -$970862.6 and a median of -$1.0 million in 2025 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 402.71% in 2025, down 1012.12% in 2025.
- Over 5 years, Other Non Operating Income stood at $14.2 million in 2022, then tumbled by 46.8% to $7.5 million in 2023, then fell by 12.22% to $6.6 million in 2024, then plunged by 115.81% to -$1.0 million in 2025, then sank by 233.91% to -$3.5 million in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$3.5 million, -$1.0 million, and -$16.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Valneva SE | 584.00 Mn | 442.75 Mn | 1.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.07 Mn |
| Mar 31, 2026 | -3.50 Mn |
| Dec 31, 2025 | -1.05 Mn |
| Sep 30, 2025 | -16.46 Mn |
| Jun 30, 2025 | 4.66 Mn |
| Mar 31, 2025 | 3.86 Mn |
| Dec 31, 2024 | 6.63 Mn |
| Sep 30, 2024 | -1.48 Mn |
| Jun 30, 2024 | 926,123.32 |
| Mar 31, 2024 | -2.73 Mn |
| Dec 31, 2023 | 7.55 Mn |
| Sep 30, 2023 | -6.49 Mn |
| Jun 30, 2023 | 1.47 Mn |
| Mar 31, 2023 | 3.40 Mn |
| Dec 31, 2022 | 14.19 Mn |
| Sep 30, 2022 | -15.97 Mn |
| Jun 30, 2022 | -8.80 Mn |
| Mar 31, 2022 | -2.71 Mn |
| Dec 31, 2021 | 3.20 Mn |
| Sep 30, 2021 | -4.01 Mn |